Impact of niraparib on reducing the platelet count in patients with ovarian cancer

Key Points

• Thrombocytopenia is a significant adverse event affecting niraparib continuation in patients with ovarian cancer.
• The study reported that monitoring platelet counts is crucial for managing treatment with niraparib.
• Real-world data was utilized to assess the impact of niraparib on platelet levels.
• Further larger-scale studies are necessary to validate these findings and improve patient outcomes.

Abstract